The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative ...
The health agency serving the LGBTQ community posted a $2.1 million operating loss in fiscal 2024, an improvement from the ...
A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...
Key market opportunities for needle-free devices lie in technological advancements, regional expansion across Asia-Pacific ...
India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for ...
Data from a new GSK survey released today highlight a potential blind spot in Respiratory Syncytial Virus (RSV) awareness ...
GSK PLC GSK shares rose 1.77% to £17.83 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.04% to 9,760.06. GSK PLC hit a ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from GlaxoSmithKline ( ...
GSK finally has the long-awaited FDA approval it sought for blood cancer drug Blenrep. Three years after the pharmaceutical giant pulled the multiple myeloma therapy from the market, the FDA approved ...
GSK won approval from the U.S. Food and Drug Administration for blood-cancer drug Blenrep, paving the way for a return to the market of a medicine the company sees as a potential blockbuster. The FDA ...
US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the world’s biggest pharmaceutical market after questions about its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback